abiraterone, Lynparza, olaparib, prednisone
Olaparib with abiraterone and prednisone (or prednisolone) is approved by FDA for BRCA-mutated metastatic castration-resistant prostate cancer
July 2023: The Food and Drug Administration (FDA) approved olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) with abiraterone and prednisone (or prednisolone) for adults with deleterious or suspected deleterious BRCA-mutated (BR..
AstraZeneca Pharmaceuticals, BRCA, gBRCAm, Lynparza, olaparib, OlympiA
Olaparib is approved for adjuvant treatment of high-risk early breast cancer
March 2022: The Food and Drug Administration has approved olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) h..